{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-030654","form_type":"8-K","ticker":"CTSO","cik":"0001175151","company_name":"Cytosorbents Corp","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.046897+00:00","generated_at":"2026-06-18T06:24:19.708915+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CytoSorbents reports FY2022 revenue down 20% to $34.7M; STAR-T enrollment past halfway","bullets":["FY2022 total revenue $34.7M, down 20% YoY; product sales $29.4M, down 27% due to COVID decline and FX.","Core product sales $29.1M; on constant currency $32.2M, down 4.6% vs 2021.","Product gross margin fell to 70% from 80% due to manufacturing relocation inefficiencies.","STAR-T pivotal trial enrollment past halfway (target 120); expected completion summer 2023.","Cash $23.8M at year-end; expect reduced cash burn and return to sales growth in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-030654","json":"https://secwatch.observer/filing/0001104659-23-030654.json","markdown":"https://secwatch.observer/filing/0001104659-23-030654.md","text":"https://secwatch.observer/filing/0001104659-23-030654.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923030654/0001104659-23-030654-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923030654/tm238762d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T06:24:19.708915+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5f75fef67893b6fac441deb9c84ee2bc87adb2bb","claim":"Cytosorbents Corp reported the quarter and year ended December 31, 2022 results: revenue Total Revenue, which includes Product Sales and Grant Income, was $34.7 million.","evidence_excerpt":"quarter and year ended December 31, 2022 and provides its 2023 outlook. Full Year 2022 Financial Results · 2022 Total Revenue, which includes Product Sales and Grant Income, was $34.7 million versus $43.2 million in 2021, a decrease of 20% · 2022 Product sales were $29.4 million versus $40.1 million in 2021, which included $0.3 million and $6.3 million in COVID-19","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923030654/0001104659-23-030654-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Revenue","value":"Total Revenue, which includes Product Sales and Grant Income, was $34.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}